Faisal Raza is a highly accomplished researcher in the field of pharmaceutics, specializing in targeted drug delivery systems for cancer therapy. With a Ph.D. from Shanghai Jiao Tong University and a Master’s from China Pharmaceutical University, Faisal has demonstrated expertise in nanomedicine, biomaterials, and pharmacology. His research focuses on developing innovative approaches for cancer treatment, leveraging his strong scientific background and analytical skills.
Author Metrics
Scopus Profile
ORCID Profile
Google Scholar Profile
Faisal Raza has a notable publication record in reputable scientific journals, reflecting his contributions to the field. His research articles have appeared in journals such as Biomaterials Science, Materials Advances, and Frontiers in Bioscience-Landmark. Additionally, Faisal serves as a reviewer for several prominent journals, showcasing his recognition and standing within the scientific community.
- Citations: 1,458
- Documents: 70
- h-index: 21
Summary
Faisal Raza, affiliated with Shanghai Jiao Tong University in Shanghai, China, has an impressive citation record, with 1,458 citations across 70 documents. His h-index, a measure of both productivity and citation impact, stands at 21, indicating that he has published at least 21 papers that have each received at least 21 citations.
Education
Faisal Raza holds a Ph.D. in Pharmaceutics from Shanghai Jiao Tong University, China, where he achieved an impressive 87% grade with an A+ rating for his thesis. He also completed his Master’s degree in Pharmaceutics from China Pharmaceutical University, Nanjing, with an 86% grade and an A+ rating for his thesis. Faisal’s educational background demonstrates his dedication to advancing his knowledge and skills in pharmaceutical sciences.
Research Focus
Faisal’s research focuses on targeted drug delivery systems for cancer therapy, with a particular interest in nanoscale formulations and biomimetic approaches. His work involves designing and evaluating novel drug carriers, such as peptide hydrogels and tumor-derived microvesicles, for precise and efficient drug delivery to cancer cells. Faisal’s research aims to improve therapeutic outcomes while minimizing side effects in cancer patients.
Professional Journey
Throughout his career, Faisal Raza has been actively involved in academic research and scientific endeavors. He has conducted research projects funded by prestigious organizations, including the National Natural Science Foundation of China and the Ministry of Science and Technology of China. Faisal’s professional journey encompasses extensive laboratory work, publication of research findings, and participation in academic conferences and forums.
Honors & Awards
Faisal has received numerous honors and awards in recognition of his academic achievements and contributions to the field of pharmaceutics. He was awarded the Outstanding Graduate of Shanghai Jiao Tong University in 2024 and has received prizes for his poster presentations at international pharmacy student forums. Additionally, Faisal has been the recipient of scholarships and certificates of excellence, further highlighting his dedication and success in academia.
Publications Noted & Contributions
Faisal Raza has made significant contributions to the scientific literature through his research publications in top-tier journals. His work on tumor-derived microvesicles for cancer therapy, pH-sensitive peptide hydrogels for retinoblastoma treatment, and thermosensitive drug-loaded liposomes for colon cancer therapy has garnered attention for its innovation and impact on the field of pharmaceutics.
“A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect against Hepatic Injury”
- Authors: J Ren, J Yan, F Raza, H Zafar, H Wan, X Chen, Q Cui, H Li, X Wang
- Published in: Recent Patents on Anti-Cancer Drug Discovery
- This study explores the synergistic effects of oleanolic acid and apatinib on liver cancer cells, highlighting their potential as a combined therapy for liver cancer treatment and hepatoprotection.
“Anticolorectal Cancer Activity of Bilobalide in Patient-Derived Colorectal Cancer Organoids and AOM/DSS Mouse Model”
- Authors: H Zhang, S Fang, F Raza, N Cao, X Fang, X Lu, R Li, F Shi, D Wang, M Xu
- Published in: European Journal of Cancer Care
- The research investigates the anti-colorectal cancer activity of bilobalide using patient-derived colorectal cancer organoids and an AOM/DSS mouse model, providing insights into potential therapeutic strategies for colorectal cancer.
“The Protective Effects of Ecdysterone on Cognitive Impairment through Regulating Akt/GSK-3β/Nrf2 Signaling Pathway and Oxidative Stress in Cognitive Mice Model and Aβ-Induced…”
- Authors: H Xing, G Chen, F Raza, H Zafar, L Xing, Q Li, R Li, S Xu, D Chen
- Published in: Frontiers in Bioscience-Landmark
- This study investigates the protective effects of ecdysterone on cognitive impairment, elucidating its mechanism of action through the Akt/GSK-3β/Nrf2 signaling pathway and oxidative stress modulation in a cognitive mice model and an Aβ-induced model.
“Isoliquiritin Ameliorates Ulcerative Colitis in Rats through Caspase 3/HMGB1/TLR4 Dependent Signaling Pathway”
- Authors: Z Miao, M Gu, F Raza, H Zafar, J Huang, Y Yang, M Sulaiman, J Yan, …
- Published in: Current Gene Therapy
- This research investigates the therapeutic potential of isoliquiritin in ulcerative colitis, highlighting its ameliorative effects through the regulation of the caspase 3/HMGB1/TLR4 dependent signaling pathway in a rat model.
“SIRT6 Reduces Rheumatoid Arthritis Injury by Inhibiting MyD88-ERK Signaling Pathway”
- Authors: X Yu, Z Jin, F Raza, P Zhang, J Wu, M Ren, J Wang, J Xi
- Published in: Frontiers in Bioscience-Landmark
- The study explores the protective role of SIRT6 in reducing rheumatoid arthritis injury by inhibiting the MyD88-ERK signaling pathway, providing potential therapeutic targets for the treatment of rheumatoid arthritis.
Research Timeline
Faisal’s research timeline spans from his doctoral studies to his current professional endeavors. Starting with his Ph.D. research on targeted drug delivery for liver cancer therapy, Faisal has continued to explore novel approaches for cancer treatment through his postdoctoral and academic research positions. His timeline reflects a progression of research projects, publications, and collaborations aimed at advancing the field of pharmaceutics.
Collaborations and Projects
Faisal Raza has collaborated on research projects funded by various national and international organizations, including the National Natural Science Foundation of China and the Guangdong Innovative and Entrepreneurial Research Team Program. His collaborative efforts have led to innovative research findings and advancements in targeted drug delivery systems for cancer therapy. Faisal’s involvement in collaborative projects underscores the importance of interdisciplinary collaboration in driving scientific progress.
